The Company has revised its outlook for the year and now expects full year revenue in the range of $95 million to $100 million compared to previous revenue guidance of 5% – 10% growth compared to the prior year’s global spine revenue of approximately $102 million. The Company’s prior guidance assumed global procedure volumes returned to normal levels in the second quarter of 2021. Our revised outlook reflects the ongoing impact of COVID-19 on demand, particularly in the global markets as well as the impact of quality issues in our global supply chain.
Investor Sentiment Improves With Powell’s Speech In Focus
U.S. stocks closed higher on Thursday, with the CNN Money Fear and Greed index remaining in the "neutral" zone.
Investor are now awaiting speech from Fed Chair Jerome Powell at the Jackson Hole symposium. Powell is scheduled to speak at 10 a.m. ET in Wyoming.
